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Electroacupuncture (EA) was investigated for lowering the blood glucose (BG) in fasting
male obese Zucker fatty diabetic (ZDF) rats aged 10e17 weeks. Anesthesia provided
satisfactory chemical restraint to enable repeated EA. Animals in Groups 1, 2 and 3 were
anesthetized on Days 1, 3, 5, 8, 10 and 12. Group 1 (n Z 4) received no EA (controls),
Group 2 (nZ 4) EA at Zhongwan and Guanyuan acupoints, and Group 3 (nZ 4) EA at both
Zusanli acupoints. BG was measured at 10 and 20 minutes, and EA was applied for 30 min-
utes, after which BG was measured again. Group 2 had a significantly lower baseline BG at
20 minutes on Days 5, 8 and 12 and significantly less change in BG over 30 minutes on Days
3 and 5 than Group 1 (p < 0.05). Group 3 showed a significant decrease in the mean base-
line BG compared to Group 1 in Week 1 (p < 0.05). Thus, repeated EA using Zhongwan and
Guanyuan acupoints was effective in lowering the baseline BG and modulating the change
in the BG in anesthetized animals.1. Introduction
Male obese Zucker diabetic fatty (ZDF) rats are much more
prone to developing hyperglycemia than females, and in
combination with the defined diet Purina 5008, have
emerged as a standard model of human type 2 diabetes.
The diabetes-like syndrome of ZDF rats is caused by aof Anatomy, University of Otago
go.ac.nz (P.V. Peplow).
acopuncture Institute
3.04.014mutation in the gene encoding the leptin receptor, result-
ing in severe dysregulation of appetite and body weight [1].
The predominant factor driving metabolic derangement is
severe adiposity-associated insulin resistance. Insulin-
sensitizing drugs such as the thiazolidinediones (e.g., pio-
glitazone) are effective in preventing hyperglycemia or
restoring normoglycemia in ZDF rats, if the treatment is, 270 Great King Street, Dunedin, New Zealand.
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of pioglitazone (12 mg/kg/day) in 2 mL/kg 5% gum arabic
initiated at 7 weeks of age for male obese ZDF rats fed with
Purina 5008, completely suppressed the development of
hyperglycemia in vehicle-treated ZDF rats over the entire
treatment period, with the fasted blood glucose (BG) being
6.4 mmol/L. The same intervention at 10e11 weeks caused
only a transient decrease of hyperglycemia [2].
A single application of electroacupuncture (EA) has been
reported to have an insulin-sensitizing effect at Zusanli
acupoints in male Wistar rats, in which type 1-like diabetes
had been induced by injection with streptozotocin [3,4]. In
addition, a single treatment of EA at the Zhongwan acu-
point in male Goto-Kakizaki rats, a genetic model of non-
obese type 2 diabetes, improved glucose tolerance by
enhancing insulin sensitivity [5]. A similar effect was found
in C57BL/KsJ-Lepdb/db mice, a genetic model of insulin
resistance and type 2 diabetes, with EA performed with
needles inserted into Zusanli and Guanyuan acupoints and
five treatments given weekly for 8 weeks [6].
This paper reports on a preliminary study of the effect of
repeated EA application in fasted male obese ZDF rats.
Treatment was given on alternate weekdays over 12 days,
with two different sets of acupoints, Zhongwan and Guanyuan
and bilateral Zusanli, being trialed. Application of EA at the
Zhongwan and Guanyuan acupoints had been shown to cause
a significant hypoglycemic response in fasted male Wistar rats
[7]. It seemed pertinent to test whether successive EA
treatment in fasted male obese ZDF rats could suppress hy-
perglycemia in this standard model of human type 2 diabetes.
2. Materials and methods
2.1. Animals
Genetically obese male ZDF rats, 10e17 weeks of age, were
obtained from a breeding colony maintained at the Taieri
Animal Station, University of Otago. The animals were fed
with Purina LabDiet Formulab 5008 (Purina LabDiet, Rich-
mond, Indiana, USA) soon after weaning and also following
delivery to the Hercus Research Unit, University of Otago.
They were housed in individual cages with free access to
food and water, in a room with an artificial 12-hour light/
12-hour dark cycle, at constant room temperature. The
obese diabetic animals were usually physically identifiable
from their lean nondiabetic littermates by 4e5 weeks of
age and ’Clinistix’ testing of their urine was done at 8e10
weeks of age. Animals were deprived of food at 4:00 PM on
the day before the experiment, to ensure an overnight fast
of at least 17 hours. This study was approved by the Uni-
versity of Otago Animal Ethics Committee.
2.2. Anesthesia
A pilot study of different anesthetics in male obese ZDF rats
was performed and the alteration in BG over 30 minutes
was measured. The change in BG for isoflurane (4% induc-
tion, 2% maintenance) in oxygen 1 L/min was 3.3 mmol/L;
for halothane (4% induction, 2% maintenance) in oxygen
1 L/min was 2.4 mmol/L; for halothane (1%) in 3:1 mixture
of nitrous oxide:oxygen 1.2 L/min was 0.9 mmol/L; and forisoflurane (1%) in 3:1 mixture of nitrous oxide:oxygen 1.2 L/
min was 1.5 mmol/L. The animals were not sufficiently
anesthetized with the latter for EA and this was also found
using ketamine (120 mg/kg, s.c.) together with 3:1 mixture
of nitrous oxide:oxygen 1.2 L/min. For this study halothane
(1%) in 3:1 mixture of nitrous oxide:oxygen 1.2 L/min was
used as the anesthetic agent.2.3. Treatment of animals
The rats were divided into four groups and those in Groups
1e3 were anesthetized with halothane (1%) in nitrous oxi-
de:oxygen on alternate weekdays, giving a total of six ap-
plications over 2 weeks. This involved placing the nose of
each animal in the nose cone of the anesthetic apparatus
and measuring BG with a hand-held glucometer (Accu-Chek
Advantage, Roche, Roche Diagnostics NZ Ltd., Mt
Wellington, Auckland, New Zealand) after needle pricking
the lateral saphenous vein of one of the hind limbs at 10
and 20 minutes. The animals in Group 1 (n Z 4) were not
treated using EA, whereas for Group 2 (n Z 4) EA was
applied using the Zhongwan (CV12) and Guanyuan (CV4)
acupoints and for Group 3 (n Z 4) using both Zusanli acu-
points. The acupoints were located using the acupoint de-
tector of the EA unit. The Zhongwan acupoint is 9/14 above
the pubic crest of the distance measured between the top
of the xiphoid process and the pubic crest, while the Gua-
nyuan acupoint is 2/14 of this distance above the pubic
crest [8]. The Zusanli (ST36) acupoints are located 5 mm
below and lateral to the anterior tubercle of the tibia. The
hair at the acupoint sites was removed with electric clip-
pers. Sterile acupuncture needles (Seirin (Seirin Corpora-
tion, Shizuoka City, Shizuoka, Japan), 0.25  15 mm) were
inserted into the muscle layer at the chosen acupoints to a
depth of 2 mm. Electrical stimulation was carried out for
30 minutes at frequency 10 Hz, pulse width 200 mS, and
intensity 15 mA, using Hans E600 EA unit (Han’s Health-
tronics, Likon, Taipei, Taiwan). The positive and negative
charges were connected to the Zhongwan and Guanyuan
acupoints, respectively. For Zusanli acupoints, the positive
and negative charges were introduced to the left and right
hind limbs, respectively. The frequency and intensity of the
electrical stimulation were monitored with an oscilloscope
located at both ends of a resistor (20 U) inserted into the
circuit. On each day at the completion of EA treatment, BG
was measured by sampling blood from the lateral saphe-
nous vein (at 50 minutes following the insertion of the nose
of the animal in the nose cone). The weights of the animals
were recorded after each treatment.
At the completion of the last application of EA and
measuring BG, the rats were given sodium pentobarbitone
(60 mg/mL in sterile saline, 0.2 mL i.p.) and blood was
collected by cardiac puncture and adipose tissue harvested
from the anterior abdominal wall, posterior abdominal
wall, mesentery and pelvic region and frozen immediately
in liquid nitrogen. The blood samples were centrifuged and
the sera stored at 20C, and the frozen adipose tissue
samples stored at 80C, until assays for glucose, insulin,
leptin and adiponectin were performed. Animals in Group 4
(nZ 6) with mean age 17 (0.2) weeks, were not exposed to
halothane (1%) in nitrous oxide:oxygen or given EA
Repeated electroacupuncture in obese diabetic ZDF rats 3treatment. They were anesthetized with sodium pento-
barbitone (60 mg/mL in sterile saline, 0.2 mL i.p.), and
blood collected by cardiac puncture and adipose tissue
harvested from the various sites and were also to be
assayed for glucose, insulin, leptin and adiponectin. The
assay data for blood sera and adipose tissue for Groups 1, 2,
3 and 4 will be presented in a separate paper.
2.4. Statistical analysis
Mean values of BG and change in BG for Groups 1, 2 and 3 on
Days 1, 3, 5, 8, 10 and 12, and also over Weeks 1 and 2,
were analyzed by analysis of variance (ANOVA) and when a
significant p value was found, a Tukey post hoc test was
performed for pairwise comparisons between the means.
Mean values of BG and change in BG for Weeks 1 and 2 were
compared for each group using Student unpaired t test.
Significance was taken to be at the level of p < 0.05.
3. Results
3.1. Choice of anesthetic
In a pilot study, halothane anesthesia (4% induction, 2%
maintenance) of fasted male obese diabetic ZDF rats caused
an increase in BG over 30 minutes of 2.4 (0.4) mmol/L, while
isoflurane (4% induction, 2% maintenance) raised BG over
30 minutes by 3.3 (0.6) mmol/L. The use of 1% halothane in
3:1 nitrous oxide:oxygen mixture was found to be satisfactory
for anesthetizing the animals sufficiently to enable blood
samples to be collected from the lateral saphenous vein of
the hind limbs and to perform EA. It also minimized the
amount of halothane that each animal was exposed to over
the course of the study. It was less satisfactory using 1%
isoflurane in 3:1 nitrous oxide:oxygen mixture, as the animals
were not sufficiently anesthetized for blood sampling or EA.
3.2. Monitoring of animals
None of the animals showed any physical signs of discom-
fort or of being stressed when examined prior to with-
drawing food or treatment the following day. They were all
physically active in their cages, their eyes were bright and
without any discharge, and their coat was clean and well
groomed. No change in body weight occurred in Week 2
compared to Week 1. The means (SE) of body weight in
Weeks 1 and 2 were, for Group 1, 423 (7) and 420 (8) g;
Group 2, 359 (9) and 361 (10) g; and Group 3, 418 (7) and
411 (6) g, respectively. The mean ages at the start of the
study were, for Group 1, 15.8 (0.3) weeks; Group 2, 12.3
(1.1) weeks; and Group 3, 15.0 (0.0) weeks. All the animals
completed the study.
3.3. Effect of EA treatment on BG
In this study, the baseline glucose level was taken to be at 20
minutes after insertion of the nose of animal into the nose
cone of the anesthetic apparatus, and at this time the ani-
mals were well relaxed. Only a small increase in BG occurred
from 10 minutes to 20 minutes (mean value of allmeasurements at 10 minutes was 8.17 mmol/L and at 20
minutes was 8.66 mmol/L), and the change in BG over a 30
minute period was measured from 20 minutes to 50 minutes.
The mean BG levels on the various days of treatment for
Groups 1, 2 and 3 are shown in Table 1. For Group 2, the
baseline BG level at 20 minutes on Days 5, 8 and 12 was
significantly lower than for Group 1 (p < 0.05), as was also
the BG level at 50 minutes on Days 3, 5 and 12 (p < 0.05). A
significant modulation of the change in BG measured over a
30 minute period was found for Group 2 compared to Group
1 on Days 3 and 5 (p < 0.05). No other significant changes
were found on comparing Group 2 or Group 3 with Group 1
(p > 0.05).
The baseline BG level for Group 2 at 20 and 50 minutes
on Day 12 was significantly lower than for Group 3
(p < 0.05). In addition, the change in BG over a 30 minute
period for Group 2 was significantly less than for Group 3 on
Days 3 and 5 (p < 0.05).
The baseline BG values and the change over 30 minutes
for Weeks 1 and 2 are presented in Table 2. For Group 1, the
baseline BG value for Week 2 was significantly lower than
for Week 1 (p < 0.05) and may have been due, in part, to
being deprived of food, but there was no significant change
in BG over 30 minutes for Week 2 compared to Week 1
(p > 0.05). No significant differences were found for Groups
2 and 3 in Week 2 compared to Week 1 (p > 0.05).
For Group 2, the baseline BG value was significantly
decreased compared to Group 1 for both Week 1 and Week
2 (p < 0.05), and the change over 30 minutes in Week 1 was
also significantly lower than for Group 1 (p < 0.05). For
Group 3, a significant decrease in baseline BG value
compared to Group 1 was found in Week 1 (p < 0.05). No
other significant changes were found on comparing values
for Groups 2 and 3 with Group 1 (p > 0.05).4. Discussion
This is the first reported study of repeated EA treatment in
an adult obese animal model of type 2 diabetes, the ZDF
rat. It was made possible by developing an anesthetic
procedure that used 1% halothane in a 3:1 mixture of
nitrous oxide and oxygen. The male obese diabetic ZDF rats
were sufficiently anesthetized using this gaseous anes-
thetic, to enable repeated blood sampling from the lateral
saphenous vein and with successive EA treatment given
three times per week on alternate weekdays. The only
other reported animal studies that used repeated EA
treatment were performed in conscious male Wistar rats 4
weeks of age [9] or conscious male Sprague Dawley rats 16
weeks of age, restrained in a plastic holder [10]. All the
other animal studies involved a single EA treatment in
anesthetized animals (usually with sodium pentobarbi-
tone), which were mainly type 1 diabetic or normal and
were terminal studies. Only one other study has used an
adult rat model of type 2 diabetes, which was the non-
obese Goto-Kakizaki rat [5].
EA was performed in fasted male diabetic ZDF rats at two
different sets of acupoints, i.e., Zhongwan and Guanyuan
(Group 2) and bilateral Zusanli (Group 3), and BG data
compared with animals not receiving any EA treatment
(Group 1). EA treatment at the abdominal acupoints had a
Table 1 Blood glucose measurements on days of treat-
ment for Groups 1, 2 and 3.
Group 1 Group 2 Group 3
Treatment 1, Day 1
20 min 12.18 (1.16) 10.25 (0.55) 9.85 (1.27)
50 min 13.35 (1.00) 10.98 (0.50) 12.03 (1.87)
Change 1.18 (0.72) 0.73 (0.54) 2.18 (0.74)
Treatment 2, Day 3
20 min 9.95 (0.88) 7.53 (0.76) 8.00 (0.43)
50 min 11.65 (1.26) 7.18 (0.75)* 9.80 (0.58)
Change 1.70 (0.50) 0.35 (0.31)* 1.75 (0.30)y
Treatment 3, Day 5
20 min 9.78 (0.77) 6.70 (0.59)* 8.00 (0.53)
50 min 11.38 (1.04) 6.55 (0.45)* 9.18 (0.33)
Change 1.60 (0.40) 0.15 (0.19)* 1.18 (0.34)y
Treatment 4, Day 8
20 min 9.73 (0.52) 7.33 (0.53)* 8.10 (0.35)
50 min 10.60 (0.93) 8.15 (0.82) 10.18 (0.91)
Change 0.88 (0.65) 0.83 (0.54) 2.08 (0.63)
Treatment 5, Day 10
20 min 8.68 (0.57) 7.15 (0.46) 8.30 (0.74)
50 min 9.68 (0.70) 7.93 (0.68) 8.93 (0.47)
Change 1.00 (0.79) 0.78 (0.35) 0.65 (0.31)
Treatment 6, Day 12
20 min 8.98 (0.39) 6.75 (0.52)* 8.63 (0.39)y
50 min 9.58 (0.32) 7.00 (0.57)* 9.95 (0.64)y
Change 0.60 (0.14) 0.25 (0.39) 1.33 (0.36)
Values are means (SE). Means tested for significant differences
between Groups 1, 2 and 3 by ANOVA and Tukey test.
There were no significant differences between Group 3 and
Group 1 (p > 0.05).
* Denotes significant difference between Group 2 and Group 1
(p < 0.05).
y Denotes significant difference between Group 2 and Group 3
(p < 0.05).
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acupoints. Baseline BG levels for Group 2 were significantly
lowered at Days 5, 8 and 12 compared to Group 1 and on Day
12 compared to Group 3, and the change in BG over a 30
minute period for Group 2 was decreased on Days 3 and 5
compared toGroup 1 andGroup 3. Thus, it would appear that
EA treatment at the abdominal acupoints is able to decrease
baseline BG levels and modulate the increase in BG that
occurred over a 30 minute period. There was no change in
baseline BG levels or modulation in the rise of BG over a 30
minute period for Group 3 compared to Group l.Table 2 Blood glucose measurements over Weeks 1 and 2 for G
Week 1
Baseline Change in 30 m
Group 1 10.63 (0.60) 1.49 (0.30)
Group 2 8.16* (0.57) 0.08* (0.24)
Group 3 8.62* (0.51) 1.70 (0.29)
Values are means (SE). Means tested for significant differences betwee
* Denotes significant difference for Group 2 or Group 3 compared t
y Denotes significant difference for Week 2 compared to Week 1 byAnalysis of the data for Weeks 1 and 2 showed that the
baseline BG for Group 2 was significantly less than for Group
1 in both Weeks 1 and 2, and that the change in BG over 30
minutes in Week 1 was significantly decreased compared to
Group 1. For Group 3, a significant change occurred in
baseline BG level in Week 1 compared to Group 1, but there
was no significant alteration in the change in BG over 30
minutes in Week 1. Thus, EA at the abdominal acupoints,
brought about glycemic control in both Weeks 1 and 2
whereas EA at the hind limb acupoints was less effective,
bringing about significant change only over Week 1. While it
is recognized that Group 2 comprised animals which were
slightly younger than those in Groups 1 and 3, there was no
significant difference in baseline BG values on Day 1 and
Day 3 for this group compared to the other two groups.
Group 2 was the only group in which the rise in BG that
occurred over 30 minutes in the presence of halothane, was
completely inhibited and replaced by a negative change on
Days 3 and 5. Furthermore, it was only for Group 2 that the
baseline BG level on Day 12 was significantly lower than
that for Group 1 and also significantly decreased from its
level on Day 1 (unpaired t test, p < 0.05). The finding that
EA at the abdominal acupoints had a more pronounced
hypoglycemic action than EA at the hind limb acupoints is
significant, as there were no previous studies of EA treat-
ment in this animal model of type 2 diabetes.
In several recent studies, it was found that regular
administration of insulin-sensitizing drugs like the thiazo-
lidinediones rosiglitazone or pioglitazone, to male obese
ZDF rats on Purina 5008, fully prevented hyperglycemia or
restored normoglycemia, if the treatment was initiated at a
young age of <9 weeks. More severe hyperglycemia pre-
vailing at ages 10e12 weeks could only be ameliorated by
thiazolidinediones, and intervention at 21 weeks of age was
without a glucose-lowering effect [2]. Our finding of a hy-
poglycemic effect in male obese ZDF rats on Purina 5008 at
a mean age of 12 weeks (Group 2) using EA at Zhongwan and
Guanyuan acupoints, is therefore very significant, and
provides a possible explanation for the less pronounced
effect of EA at Zusanli acupoints in animals at a mean age
of 15 weeks (Group 3), which would have been at a later
stage of metabolic derangement.
In conclusion, repeated EA treatment at the Zhongwan
and Guanyuan acupoints lowered the fasted baseline BG
level from 10.25 mmol/L on Day 1 to 7.53 mmol/L and
6.75 mmol/L on Day 3 and Day 12, respectively, and did not
have any apparent adverse effect on the wellbeing of the
animals. The BG of fasted non-diabetic lean ZDF rats of a
comparable age was reported to be 5 mmol/L [2]. Furtherroups 1, 2 and 3.
Week 2
in Baseline Change in 30 min
9.13y (0.30) 0.83 (0.31)
7.08* (0.27) 0.62 (0.25)
8.34 (0.28) 1.35 (0.30)
n Groups 1, 2 and 3 in Week 1 or Week 2 by ANOVA and Tukey test.
o Group 1 (p < 0.05).
Student unpaired t test (p < 0.05).
Repeated electroacupuncture in obese diabetic ZDF rats 5studies are warranted to test the effect of repeated EA at
the abdominal and hind limb acupoints in male obese dia-
betic ZDF rats over a longer period, and also of different
ages. EA has been given to human patients with type 2
diabetes and the reduction in BG was more pronounced
with an increasing number of treatments, with fasted BG
lowered from 8.1 to 6.2 mmol/L after 3 months of treat-
ment [11].
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